endothelial cells. The restricted expression of PLP-J and its specific interactions with uterine stromal cells and endothelial cells suggests that it acts locally and regulates decidual cell development and the endometrial vasculature.
Successful pregnancy requires specialized maternal adaptations. Decidualization is a key uterine adaptation associated with the establishment of pregnancy and is characterized by the differentiation of uterine stromal cells (1) (2) (3) (4) .
Decidual cell differentiation is dependent upon ovarian steroid hormone production and in rodents, also requires signals emanating from the preimplantation embryo (1, 5) . Once formed, decidual cells establish a protective environment facilitating the development of the placenta and embryo. They promote the redistribution of specific populations of leukocytes and reorganize the uterine vascular network. Intercellular signals elaborated by decidual cells are key mediators of these uterine adaptive responses.
Among the decidual cell ligands are a family of cytokines related to prolactin (PRL).
PRL is an ancient hormone with its origins as a regulator of vertebrate environmental adaptations (6, 7) . Some species possess a single member of the PRL family that can be expressed in an assortment of tissues including the anterior pituitary and uterus through the utilization of cell-specific promoters (8) (9) (10) .
Other species have undergone a gene expansion within the PRL locus (11) . PRL family gene expansion is particularly robust in the mouse and rat (12) (13) (14) . Gene duplication and natural selection have yielded two dozen related genes in each of these species. The PRL family genes encode cytokines/hormones that are expressed in cell-and temporal-specific patterns and are most relevant to pregnancy-associated tissues, especially in the uterine decidua and the placenta. Initial observations suggest that the expanded PRL family participates in pregnancy-dependent adaptations to physiological stressors (15, 16) . Although a few members are PRL mimetics (placental lactogens, PLs), activating PRL receptor signaling cascades, most utilize distinct strategies to regulate their cellular targets (11, 17) . The cellular targets are intriguing and include endothelial cells, inflammatory/immune cells, and hematopoietic precursors (18) (19) (20) (21) (22) .
Decidual cells of the mouse and rat express four members of the PRL family: PRL (23, 24) , PRL-like protein-B (PLP-B, also known as PRL family 6, subfamily a, member 1, Prl6a1) (25) (26) (27) (28) , decidual PRLrelated protein (dPRP, also known as PRL family 8, subfamily a, member 2, Prl8a2) (27, 29, 30) , and PLP-J (also known as PRL family 3, subfamily c, member 1, Prl3c1) (31) (32) (33) (34) . PRL is postulated to be expressed in rodent decidual cells under the direction of a unique cell specific promoter, as has been characterized for human decidual cells (10, 35) , where it acts through the PRL receptor signaling pathway to promote decidual cell survival, regulate leukocyte function, stimulate uterine gland development, and facilitate vascular remodeling (23, (36) (37) (38) . PLP-B and dPRP do not utilize the canonical PRL receptor signaling pathway (22, 26, 39) .
DPRP is a heparin binding cytokine which is essential for pregnancy-dependent adaptive responses to hypoxia (16, 22, 39) . Unlike wild-type animals, mice deficient in dPRP do not effectively adapt to hypoxia and terminate their pregnancies. DPRP modulates decidual expression of PLP-J but not PLP-B or PRL (16) . The expression of PLP-J is significantly decreased in dPRP null mice, suggesting that the biology of dPRP and PLP-J may be linked.
Information on the biological functions of PLP-J is not available.
In this study, we have characterized the PLP-J protein and its expression pattern, identified targets for its action, and determined biological responses of its cellular targets. PLP-J is a heparin-binding cytokine with distinct actions on uterine stromal cell and endothelial cell populations.
Experimental Procedures

Animals and tissue preparation
Holtzman rats were obtained from Harlan Sprague-Dawley Inc. (Indianapolis, IN) . The animals were housed in an environmentally controlled facility, with lights on from 0600 to 2000 h, and allowed free access to food and water. Timed pregnancies were generated and tissue dissections were performed as previously detailed (40) . Conceptuses with associated uteri were removed on specific days of gestation. Tissues were frozen in dry ice-cooled heptane and stored at -80ºC until used for in situ hybridization, immunohistochemistry, and in situ ligand binding or were frozen in liquid nitrogen and stored at -80ºC for subsequent RNA and protein analyses. The presence of sperm in the vaginal smear was designated as day 0.5 of pregnancy. New Zealand White rabbits were obtained from Myrtle's Rabbitry (Thompsons Station, TN) and used for antibody production. Protocols for the care and use of animals were approved by the University of Kansas Animal Care and Use Committee.
Cell culture
U1 rat uterine stromal cells were obtained from Dr. Virginia Rider (Pittsburgh State University, Pittsburg, KS) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, and penicillin (100 units/ml) and streptomycin (100 µg/ml) (41, 42) . These rat uterine stromal cells are physiologically relevant in that they can be induced to differentiate into decidual cells (43) . Rat aortic endothelial cells were purchased from VEC Technologies, Inc. (Rensselaer, NY) and maintained in MCDB-131 Complete culture medium. The rat Nb2 lymphoma cell line was provided by Dr. Peter Gout (University of British Columbia, Vancouver, BC, Canada) and maintained in RPMI 1640 culture medium supplemented with 10% horse serum, 10% FBS, 50 μM 2-mercaptoethanol, 2 mM L-glutamine, 5 mM HEPES , penicillin (50 units/ml), and streptomycin (50 µg/ml) (44) . Human embryonic kidney (HEK 293) cells were obtained from American Type Culture Collection (ATCC, Rockville, MD) and used as a host for the expression of the PLP-J fusion proteins. HEK 293 cells were maintained in DMEM/F12 medium supplemented with 10% FBS, 1 mM sodium pyruvate, penicillin (100 units/ml), and streptomycin (100 µg/ml). CHO cells and heparan sulfate deficient CHO-pgsD-677 cells were obtained from ATCC and cultured in DMEM/MCDB 302 culture medium containing 100 units/ml of penicillin, 100 μg/ml of streptomycin, and 10% FBS. Raji cells stably transfected with a syndecan-1 (Sdc1) expression vector (Raji-S1) and the parent Raji cell line were obtained from Dr. Alan C. Rapraeger (University of WisconsinMadison, Madison, WI) and were maintained in RPMI 1640 culture medium supplemented with 10% FBS and antibiotics (45) . All cell cultures were maintained in a humidified atmosphere of 5% CO 2 /95% air at 37ºC.
Generation of fusion proteins
mFLAG-PLP-J. PLP-J was expressed as a fusion protein with a FLAG-6xHis-FLAG tag. The full length mature rat PLP-J cDNA was used as a template for PCR amplification of a PLP-J fragment with EcoR1 and Xba1 restriction sites at the 5'-and 3'-ends, respectively, using sequence specific primers, 5'-cat tta aag aat tca cac cat atg acc aga tgt-3' and 5'-gtt ata tgt ttc tag att acc act tgt taa taa tg-3'. After digestion with EcoR I and Xba I restriction enzymes, the fragment was ligated into a modified pFLAG-CMV-3 vector (mFLAG; Sigma-Aldrich, St. Louis, MO). The accuracy of vector construction was verified by DNA sequencing. The mFLAG-PLP-J plasmid was transfected into HEK 293 cells using Lipofectamine Plus according to the manufacturer's instruction (Invitrogen, Carlsbad, CA). Initial selection of transfected cells was accomplished in the presence of G418 at a concentration of 500 μg/ml. Selected cells were then maintained in 100 μg/ml of G418.
The mFLAG-PLP-J fusion protein was purified from serum-free conditioned medium by incubating with a Ni-NTA agarose resin (Qiagen, Valencia, CA). In brief, Ni-NTA agarose was equilibrated with Sorensen's phosphate buffer (NaH 2 PO 4 , 66 mM and KH 2 PO 4 , 66 mM) and added to conditioned medium in a buffer containing 10 mM imidazole, 50 mM NaH 2 PO 4 , 0.15 M NaCl, pH 8.0 (1X binding buffer), incubated overnight at 4ºC with constant shaking. The resin was then transferred into a column and washed with 2X binding buffer. Recombinant mFLAG-PLP-J protein was eluted with 250 mM imidazole and 0.15 M NaCl in Sorensen's phosphate buffer, pH 6.0. Aliquots of fractions were separated using sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie Blue G-250 and immunoblotted with anti-Flag M2 antibody (Sigma-Aldrich).
Immunopositive fractions were pooled and dialyzed against phosphate buffered saline, pH 7.4 (PBS) and concentrated by Centricon ultrafiltration centrifugation devices (Millipore, Billerica, MA). Purified proteins were sterilized using Millex filters Alkaline phosphatase (AP)-PLP-J fusion protein (AP-PLP-J). The full length cDNA for mature rat PLP-J was ligated downstream of heat stable human placental AP of pCMV-SEAP and then transfected into HEK 293 cells as previously described (46, 47) . The transfected cells were selected and maintained in DMEM/F12 culture medium supplemented with 10% FBS and G418 as described above. Cells were transferred to serum-free culture medium for 72 h. Conditioned medium was collected and cellular debris removed by centrifugation at 2,200 xg for 30 min at 4ºC and then stored at -20ºC.
AP activity was quantified by colorimetric assay at 405 nm using p-nitrophenyl phosphate as an AP substrate (47) . AP-fusion proteins were also separated using SDS-PAGE, electrophoretically transferred to nitrocellulose, and AP activity detected by incubation with nitroblue tetrazolium and bromochloroindolyl phosphate (NBT/BCIP).
Preparation of PLP-J antibodies
Antibodies directed to PLP-J were prepared by immunizing rabbits with recombinant 6xHis tagged PLP-J protein generated in a prokaryotic expression system, pQE-30Xa (Qiagen). The mature rat PLP-J cDNA was used as a template for PCR amplification of a PLP-J fragment with BamH1 and Sac1 restriction sites at the 5'-and 3'-ends, respectively, using sequence specific primers, 5'-cat tta aag gat cca cac cat atg acc aga tgt-3' and 5'-gtt ata tgt cga gct ctt acc act tgt ttt taa taa tg-3'. The amplified fragment was ligated into the pQE-30Xa plasmid and transformed into E.coli, M15[pREP4]. 6xHis-PLP-J expression was induced by 2 mM isopropyl β-D-1-thiogalactopyranoside and 6xHis-PLP-J protein was purified from bacterial exclusion bodies by Ni-NTA agarose affinity chromatography as described above. Purified 6xHis-PLP-J was characterized by SDS-PAGE and western blotting with anti-His tag antibodies (Qiagen). Purified 6xHis-PLP-J was used to immunize New Zealand White rabbits as previously described (48, 49) .
Western blot analysis of decidual tissues
Protein lysates were prepared by homogenizing gestation day 8.5 rat conceptuses (decidua and extraembryonic and embryonic tissues) in RIPA buffer (10 mM Tris-HCl, pH 7.2, 1% Triton X-100 or 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin). Protein concentrations were determined by the DC protein assay (Bio-Rad). Fifty μg of total protein were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Immunoreactive PLP-J and dPRP were detected with antibodies to anti-PLP-J (present study) and anti-dPRP (39), respectively, and visualized by enhanced chemiluminescence according to the manufacturer's instructions (Amersham Biosciences, Piscataway, NJ).
Immunocytochemistry
Immunocytochemical analyses were used to localize PLP-J and dPRP proteins and the distribution of endothelial cells in gestation day 8.5 implantation sites, as described (39, 40, 50) . Cryosections (10 µm) were prepared, fixed in cold 4% paraformaldehyde solution, and blocked in 10% normal goat serum for 1 h at room temperature. The immunodetection was performed by incubating overnight at 4ºC with anti-PLP-J (present study), anti-dPRP antibodies (39), or with RECA-1 antibodies, which recognize an uncharacterized rat endothelial cell-specific surface antigen (Serotec, Oxford, UK) (41). Avidin-peroxidase conjugated secondary antibody was added for 30 min at room temperature and color developed with an AEC kit (Zymed Laboratories, San Francisco, CA). Tissues were counterstained with at University of Kansas Medical Center/ A R Dykes Library on May 9, 2008 www.jbc.org
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Mayer's hematoxylin. Images were captured using a Leica MZFIII steromicroscope (Leica Microsystems GmbH, Welzlar, Germany) or a Nikon Eclipse 55i microscope (Nikon Instruments Inc., Melville, NY), both equipped with Leica CCD cameras (Leica).
In situ hybridization
In situ hybridization was performed to assess the distributions of PLP-J and dPRP transcripts in gestation day 8.5 rat implantation sites, (40, 51) . Cryosections (10-μm) were prepared and stored at -80ºC until used. Plasmids containing cDNAs for PLP-J (34) and dPRP (29) were used as templates to synthesize sense and antisense digoxigeninlabeled riboprobes according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN). The frozen sections were air-dried and fixed in cold 4% paraformaldehyde in phosphate-buffered saline. Prehybridization, hybridization, and detection of alkaline phosphatase-conjugated anti-digoxigenin were performed as previously reported (12, 51) . Images were captured as described above.
Northern blot analysis
Northern blot analysis was performed as previously described (52) . Total RNA was extracted from gestation day 8.5 rat decidual tissues, UI uterine stromal cells, and rat aortic endothelial cells using TRIzol reagent (Invitrogen). Total RNA (15 μg per lane) was resolved in 1% formaldehyde-agarose gels, transferred to nylon membranes and crosslinked. Blots were probed with [32P]-labeled cDNAs for syndecans (Sdc1, NM_013026; Sdc2, NM_013082; Sdc3, NM_053893;
Sdc4, NM_012649). Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) cDNA was used to evaluate the integrity and equal loading of RNA samples. At least three different tissue samples from three different animals were analyzed with each probe for each time point.
AP-PLP-J binding
Tissues. An in-situ AP-binding assay was performed as previously described (46, 47) . In brief, 8-10 μm tissue sections were prepared with a cryostat and mounted onto glass slides. The tissue sections were washed with a modified Hank's balanced salt solution (HBHA; containing 20 mM HEPES, 0.5 mg/ml BSA and 0.1% NaN3) and incubated with AP, AP-PLP-J, or AP-placental lactogen-I (PL-I, also known as PRL family 3, subfamily d, member 1, Prl3d1) fusion protein (46) 
Heparin binding assay
PLP-J and dPRP interactions with heparin were evaluated with a heparin-binding plate assay (55) . Multi-well plates were coated with either heparin conjugated to bovine serum albumin (heparin-BSA, SigmaAldrich) or BSA (Sigma-Aldrich) and incubated with AP-PLP-J, AP-dPRP, or AP. Wells were washed with HBHA containing 0.1% Tween 20 and HBSS. AP activity was determined by incubation with AP substrate (p-nitrophenyl phosphate) and measurement of absorbance at 405 nm.
Cell adhesion assay
Cell adhesion assays were performed as described (56) . 96-well microtiter plates were coated with test proteins diluted in PBS (50 μl/well) and incubated at 4ºC for 16 h. Wells were washed three times with PBS and blocked with 1% BSA at room temperature for 1 h. To test for specificity, anti-PLP-J serum or normal rabbit serum was added to the wells and incubated for 1 h at 37ºC prior to plating of cells. Cells were harvested in normal growth medium, washed with HBSS, and resuspended at 5 x 10 5 cells/ml in serum free normal growth medium. Where indicated, cells were incubated with heparin prior to plating for 1 h at room temperature. A 50 µl cell suspension was added to each well and incubated 30 min at 37ºC. Adherent cells were fixed in 10% formalin in saline for 30 min at room temperature. The cells were stained with methylene blue, and adhesion was quantified by dye extraction and measurement of absorbance at 620 nm (56) .
Nb2 lymphoma cell proliferation assay
The Nb2 lymphoma cell proliferation assay was performed with some modifications to the previously published procedure (44) . Twentyfour h before initiating the assays, cells were incubated with RPMI1640 supplemented with 5% horse serum, 2 mM L-glutamine, 5 mM HEPES and antibiotics (Assay Medium) to establish a quiescent state. Cells were washed with Assay Medium, counted with a hemocytometer, and distributed to wells in a 96 well plate (2.5 x 10 4 cells/well). Cells were incubated with ovine PRL (0.1, 1, or 10 ng/ml; NOBL Laboratories, Inc., Sioux Center, IA) or mFLAG-PLP-J (0.1, 1, or 10 μg/ml) for 72 h. Viable cells were quantified by the CellTiter 96 AQ uous Non-Radoiactive Cell proliferation assay (Promega, Madison, WI).
Rat uterine stromal cell proliferation assay
Rat UI uterine stromal cells were harvested by trypsin-EDTA, washed, and resuspended in DMEM medium supplemented with 10% FBS, 1 mM sodium pyruvate, and 100 units/ml penicillin and 100 µg/ml streptomycin. Cells were distributed in 96-well plates at a density of 1 x 10 3 cells per well and incubated for 24 h. To initiate the assays, cells were starved for 24 h with DMEM medium containing 1% FBS. Cells were then treated with mFLAG-PLP-J (0.01, 0.1, 1, or 10 μg/ml) or fibroblast growth factor 2 (FGF2, 10 ng/ml; R&D Systems, Minneapolis, MN) for 24, 48, or 72 h. Numbers of viable cells were measured by CellTiter 96 AQ uous Non-Radoiactive Cell proliferation assay (Promega) at the indicated times. To assess DNA synthesis, cells were grown as described above and distributed in 24-well plates. Bromodeoxyuridine (BrdU, SigmaAldrich) was added to the medium (10 μM) for 16 h in the presence or absence of mFLAG-PLP-J. BrdU incorporation was detected using a BrdU staining kit (BD Pharmingen, San Jose, CA).
Endothelial cell proliferation assay
Rat aortic endothelial cells were harvested by trypsin-EDTA, washed, and resuspended in complete MCDB-131 medium. The cells were distributed in 48-well plates at a density of 4 x 
Cell proliferation monitored by crystal violet staining
Proliferation indices of UI rat uterine stromal cells and rat aortic endothelial cells were also evaluated morphologically by crystal violet staining, as previously described (57, 58) . Cells were harvested with trypsin-EDTA, washed, resuspended at 5 x 10 4 cells/ml in growth medium, distributed in 48-well plates, and cultured for 24 h. Cells were washed and pre-incubated with medium containing 1% FBS for 24 h. Test proteins were then added to the cells. At the indicated time intervals, cells were stained with 0.1% crystal violet for 10 min, washed with distilled water, and dried at room temperature. Images of cells were captured with a Leica MZFIII stereomicroscope equipped with a CCD camera (Leica).
Statistical analysis
Statistical comparisons between two means were determined with Student's t-test. Comparisons among multiple means were evaluated with analysis of variance. The source of variation from significant F-ratios was determined with Bonferroni's Multiple Comparison test (59) .
RESULTS
Generation of PLP-J fusion proteins and antibodies
PLP-J was engineered to be expressed in recombinant form containing FLAG and 6x His tags at its N-terminus (mFLAG-PLP-J) in HEK 293 cells. Purified mFLAG-PLP-J consisted of three species with molecular weights ranging from approximately 31 to 37 kDa (Fig. 1A) . PLP-J possesses two putative N-linked glycosylation sites (31) (32) (33) (34) and thus differential glycosylation may account for the mFLAG-PLP-J size variants. mFLAG-PLP-J was used as a ligand to evaluate PLP-J cellular actions (see below). PLP-J was also expressed as a 6x His-tagged fusion protein in a bacterial expression system. The 6x Histagged PLP-J fusion protein migrated predominantly as a 26 kDa protein (Fig. 1B) and was used an immunogen in rabbits. PLP-J antibodies reacted with both the mFLAG-PLP-J and 6x His-tagged PLP-J fusion proteins (Fig. 1A and 1B) . AP and AP-PLP-J fusion proteins were generated in HEK 293 cells (Fig. 1C) and used as probes to assess PLP-J interactions with putative cellular and molecular targets.
Intrauterine PLP-J expression and binding
PLP-J expression patterns and PLP-J targets were investigated. The distributions of PLP-J and dPRP mRNAs within the uterus of pregnant rats were assessed by in situ hybridization and were consistent with earlier reports (29, 30, 32, 34) .
PLP-J and dPRP mRNAs were predominantly observed in the uterine decidua, especially within the antimesometrial decidua ( Fig. 2A and D) . PLP-J and dPRP protein immunolocalizations mirrored the distribution of PLP-J and dPRP mRNAs ( Fig. 2B and E) . Decidual PLP-J migrated as a single 29 kDa protein and thus differed from the multiple molecular species of recombinant HEK 293 cell-engineered mFLAG-PLP-J (Fig. 2F) . The specificity of the PLP-J immunoreactivity was demonstrated by competition with purified mFLAG-PLP-J (Fig. 2C and F, lanes 2 and 4) . PLP-J interactions with structures within at University of Kansas Medical Center/ A R Dykes Library on May 9, 2008 www.jbc.org Downloaded from gestation d8.5 implantation sites were also investigated (Fig. 3) . AP-PLP-J binding was detected throughout the uterus and was particularly evident in association with the uterine vasculature (Fig. 3B,C,D ,F,G, and H) and the undifferentiated uterine stromal cell compartment (Fig. 3D) .
Intrauterine distributions of AP-PLP-J binding and RECA-1 immunoreactivity (a rat endothelial cell-specific antibody) overlapped. Intrauterine AP-PLP-J binding was specific ( Fig. 3J and K) and could be competed by mFLAG-PLP-J (Fig. 3K), heparin (Fig. 3L) , heparan sulfate (Fig. 3M) , dermatan sulfate ( Fig. 3O) but not chondroitin sulfate A or C ( Fig. 3N and P) . In summary, PLP-J protein is synthesized by uterine decidual cells situated proximal to the developing embryo and specifically interacts with intrauterine structures, especially the vasculature, in a heparin/heparan sulfate-and/or dermatan sulfate-dependent manner.
PLP-J interacts with heparin
Based on the heparin-dependence of the AP-PLP-J-uterine tissue binding, we further investigated PLP-J-heparin interactions. DPRP, another decidual cell cytokine, also specifically interacts with heparin (22, 39) and was used as a positive control in some of the analyses. AP-PLP-J and AP-dPRP specifically bound heparin-BSA coated plates but not BSAcoated plates, whereas AP did not bind to either plate (Fig. 4A) . AP-PLP-J also exhibited binding to CHO cells that was dependent upon the presence of heparan sulfate ( Fig. 4B and C) . Additional PLP-J-cellular interactions that are potentially physiologically relevant (uterine stromal cells and endothelial cells, see Fig. 3 ) were assessed.
AP-PLP-J specifically interacted with both uterine stromal cells (Fig.  5A ) and endothelial cells (Fig. 5C) . Heparin was an effective competitor of AP-PLP-J binding to uterine stromal cells (Fig. 5B ) but was less effective in competing with AP-PLP-J binding to endothelial cells (Fig. 5D) .
Collectively, the results indicate that PLP-J associates heparin containing molecules, potentially located in extracellular matrices and on cell surfaces.
PLP-J interacts with syndecans
Syndecans are a family of four transmembrane proteins possessing heparan sulfate sugar chains associated with their extracellular domains (60, 61) . They have been implicated in cell adhesion and growth factor signal transduction and were considered molecular candidates for PLP-J interaction with its target cells. Initially uterine decidua, uterine stromal cells, and endothelial cells were assessed for their expression of syndecan family members by northern blotting (Fig. 6A) . Gestation day 8.5 uterine decidua expressed Sdc1 and Sdc4 mRNAs, whereas uterine stromal cells and endothelial cells expressed only Sdc1 mRNA. Sdc2 and Sdc3 were not detected in decidua and the two cell populations. Raji cells are devoid of heparan containing molecules on their surfaces and represent a useful cell model for testing the biology of specific heparan sulfate proteoglycans (45) . The ability of PLP-J to bind syndecans was evaluated in Raji cells genetically engineered to express Sdc1 (45). AP-PLP-J interactions with Raji cells were shown to be dependent upon the surface expression of Sdc1 (Fig. 6B) . Thus, syndecans are expressed in the uterine decidua and are potential mediators of PLP-J-cellular interactions.
PLP-J does not activate the canonical PRL receptor signaling pathway
A subset of members of the PRL family influence target cell function through activation of the PRL receptor signaling pathway (11) . This subset includes PRL, PL-I, and PL-II (also known as PRL family 3, subfamily b, member 1, Prl3b1). Interestingly, PLP-J is also a member of the PL-I and PL-II subfamily. Its interactions with the PRL receptor signaling pathway were evaluated in the next series of experiments. Initially, binding experiments were performed with heparan sulfate deficient CHO-pgsD-677 cells transfected with an expression vector containing the long form of the rat PRL receptor. AP-PL-I effectively interacted with the engineered cells; whereas AP-PLP-J was ineffective (Fig. 7A-D) . AP-PLP-J was also ineffective in binding to tissue sections of the rat corpus luteum and liver, tissues with abundant PRL receptor expression (Fig . Fig. 7E-J) .
Rat Nb2 lymphoma cell proliferation has been used as a bioassay for canonical PRL receptor activation (44) .
PRL stimulated Nb2 lymphoma cell proliferation; however, PLP-J was ineffective (Fig. 7K) .
The results indicate that PLP-J is not a PRL receptor agonist.
PLP-J promotes uterine stromal cell and endothelial cell adhesion
Since PLP-J interacts with heparin containing molecules and heparin-related molecules are located on the cell surface of uterine stromal cells and endothelial cells, we next assessed the effectiveness of PLP-J in promoting uterine stromal cell and endothelial cell adhesion. In these experiments, fibronectin was used as a positive control and PRL as a negative control.
PLP-J and fibronectin facilitated both uterine stromal cell and endothelial cell adhesion, whereas PRL was ineffective ( Fig. 8A and D) . Co-incubation with heparin decreased cellular adhesion to PLP-J. Heparin was more potent in interfering with PLP-J-mediated endothelial cell adhesion (Fig. 8E) than with PLP-J-mediated uterine stromal cell adhesion (Fig. 8B) .
PLP-Jdependent adhesion was also disrupted by coincubation with PLP-J antibodies (Fig. 8C and  F) . The same antibodies did not interfere with fibronectin-mediated cellular adhesion. The findings indicate that PLP-J can act as an adhesion molecule for both uterine stromal cells and endothelial cells.
PLP-J modulation of uterine stromal cell and endothelial cell proliferation
Uterine stromal cells and endothelial cells undergo dynamic changes during the establishment of pregnancy (1-4) . The effects of PLP-J in modulating uterine stromal cell and endothelial cell proliferation were investigated with three complementary assays (Figs. 9 and  10 ). PLP-J stimulated uterine stromal cell proliferation (Fig. 9A-E ) and uterine stromal cell incorporation of BrdU (Fig. 9F) . In contrast, PLP-J inhibited endothelial cell proliferation and endothelial cell incorporation of BrdU (Fig. 10F) . The effects of PLP-J on its cellular targets were most impressive after 72 h of incubation (Figs. 9C and 10C ). The minimal effective PLP-J concentration was 1 μg/ml (Fig. 9B and C and Fig. 10B and C) . PLP-J also inhibited FGF2 stimulated endothelial cell proliferation (Fig. 10G) . In summary, PLP-J stimulates uterine stromal cell proliferation and inhibits endothelial cell proliferation.
DISCUSSION
Evidence is accumulating for the involvement of the PRL family of cytokines in the regulation of maternal adaptations to pregnancy (11) . In this report, we provide insights into a role for PLP-J, a member of the PRL family, in controlling intrauterine events during the establishment of pregnancy. The PLP-J protein was characterized and its molecular and cellular interactions investigated. PLP-J is expressed in uterine decidual cells and is a heparin binding cytokine with potential paracrine actions on stromal and vascular cell development.
PLP-J is an intrauterine cytokine. The PLP-J protein is localized to a subpopulation of decidual cells situated proximal to the developing embryo (present study). This observation is consistent with earlier reports (22, 27, 29, 30, 39) . PLP-J expression is also positively modulated by dPRP (16) . This relationship may be indirect through dPRP promotion of decidual cell survival. In the human, PRL is the sole member of the PRL family (11, 62) . It is expressed in both pituitary and extrapituitary sites, including decidual cells, and also possesses heparin binding properties (9, 10, 63) . Rodent PRLs and most members of the PRL family do not exhibit heparin binding characteristics. The decidual cell expression of PLP-J, dPRP, and human PRL and their restricted distribution through interactions with heparin-containing molecules suggest that they act locally as cytokines within the vicinity of the embryo implantation site.
PLP-J interacts with and regulates specific cellular constituents of the uterus. Stromal cells and endothelial cells are among the putative intrauterine PLP-J targets. PLP-J can promote uterine stromal and endothelial cell adhesion. These interactions are mediated, at least in part, through heparin containing molecules. Heparin-containing molecules are prominently displayed on the plasma membrane of cells and within the extracellular matrices of tissues (64) . These molecules modulate development and are disrupted in some disease processes. PLP-J may not discriminate and instead associate with any uterine cell type possessing surface heparan sulfate proteoglycans in its proximity. Stromal cells and endothelial cells are prominent components of the preimplantation uterus, which undergo marked changes following embryo implantation (3, 5) . Stromal cells serve as precursors for decidual cell differentiation and endothelial cells line the intrauterine vasculature. During the establishment of pregnancy in the mouse and rat, the intrauterine vasculature undergoes specific regional modifications (3, 5, 65) . Blood vessels in the mesometrial compartment (site of the developing chorioallantoic placenta) are significantly expanded in comparison to the anti-mesometrial uterine vasculature. In our in vitro analysis, PLP-J differentially affected the behavior of uterine stromal cells and endothelial cells.
PLP-J stimulated proliferation of uterine stromal cells, while inhibiting the proliferation of endothelial cells. These results indicate that PLP-J is a biologically active cytokine with the potential to regulate the intrauterine environment. The in vivo biological impact of decidual cell PLP-J production will be influenced by its access to its cellular targets and its relative contribution to the milieu of other growth factors and cytokines elaborated at the uteroplacental interface.
Relevant biologically active concentrations are difficult to determine for PLP-J. The heparin-binding properties of PLP-J will direct PLP-J to the cell surface or extracellular matrix where it will have a juxtacrine mode of action. Thus in an in vivo setting, PLP-J is sequestered and requires liberation from its tether to find its targets or alternatively, the cellular targets may have to be brought to the sequestered PLP-J.
PLP-J modulates cell activities through mechanisms that are not yet defined. Some insights about PRL family member activation of signal transduction cascades are available. A subgroup of PRL family members (PRL, PL-I, and PL-II) utilizes the canonical PRL receptor signaling pathway (11) . Among all members of the PRL family, PLP-J is most similar in amino acid sequence to the PLs (31-34) ; however, PLP-J does not bind to or activate the PRL receptor (present study). Apparently, the critical amino acids dictating PRL receptor recognition are not present in PLP-J. Other differences from its closest relatives (PL-I and PL-II) are also evident. PLP-J possesses a domain(s) facilitating interactions with heparin containing molecules.
This ligand-directed heparin binding may be a key to understanding the cellular actions of PLP-J. Some heparan sulfate proteoglycans, such as syndecans, are transmembrane proteins capable of interacting with heparin-binding growth factors and mediating the activation of signal transduction cascades (66, 67) . Decidual cells, uterine stromal cells and endothelial cells express members of the syndecan family and PLP-J specifically binds to Sdc1. Thus, PLP-J could modulate cellular action directly via engaging transmembrane heparan sulfate proteoglycans (such as syndecans) or by interfering with the actions of other heparin-binding growth factors (e.g. FGFs) that utilize transmembrane heparan sulfate proteoglycans. Differential expression of heparan sulfate proteoglycans could be responsible for the distinct effects of PLP-J on uterine stromal cells versus endothelial cells. Components of PLP-J activities were independent of interactions with heparin containing molecules, suggesting that there may be additional modes of PLP-J action for some of its cellular targets. Among these may be interactions with specific membrane-associated receptor signaling pathways or possibly other glycosaminoglycans, including dermatan sulfate. PLP-J is capable of interacting with dermatan sulfate and the uterine endometrium possesses dermatan sulfate proteoglycans (68) . However, possible roles for dermatan sulfate proteoglycans in modulating PLP-J signaling are yet to be determined.
The PRL gene family expanded during the evolution of rodents (11, 17) . New genes were derived from an ancestral template, which encode hormones and cytokines that are linked to viviparity and reproductive adaptations. PLP-J is part of the expanded rodent PRL family. It possesses a unique intrauterine tissue distribution and a novel intrauterine mode of action that is mediated, at least in part, through interactions with heparan sulfate proteoglycans . 
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